All News

FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.

Anna Taddio, PhD, explains why the 2026 guideline on vaccine distress treats vaccine pain and fear as a safety issue and what primary care clinicians should know.

Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.

EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.

Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.

Bleeding fears, skipped doses, and cost leave many patients with atrial fibrillation unprotected from stroke. A cardiologist and vascular medicine specialist explains.

September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.

EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.

EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.

Geoffrey Barnes, MD, on why a careful exam is the first line of detection and which 2 risk factors primary care clinicians can actually change.

The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.

Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.

Daniel Drucker, MD, discusses gastrointestinal effects, hydration, pregnancy planning, and unanswered long-term safety questions.

The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.

An endocrinologist discusses the importance of history, comorbidities, lifestyle care, and outcomes beyond weight loss when choosing obesity treatment.

New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.

FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.